Multiple biomarkers are involved in the pathogenesis of GBM (7, 8)—for instance, the PI3K/Akt/mTOR signaling pathway has been implicated as a potential target for GBM therapy (9–11). The gene discussed is MTOR; the disease is glioblastoma.